7VUN
Design, modification, evaluation and cocrystal studies of novel phthalimides regulating PD-1/PD-L1 interaction
7VUN の概要
| エントリーDOI | 10.2210/pdb7vun/pdb |
| 分子名称 | Programmed cell death 1 ligand 1, (2~{S},3~{S})-2-[[6-[(3-cyanophenyl)methoxy]-2-(2-methyl-3-phenyl-phenyl)-1,3-bis(oxidanylidene)isoindol-5-yl]methylamino]-3-oxidanyl-butanoic acid (3 entities in total) |
| 機能のキーワード | dimer, beta-sheet, structural protein |
| 由来する生物種 | Homo sapiens (human) |
| タンパク質・核酸の鎖数 | 8 |
| 化学式量合計 | 117522.16 |
| 構造登録者 | Cheng, Y.,Sun, C.L.,Chen, M.R.,Yang, P.,Xiao, Y.B. (登録日: 2021-11-03, 公開日: 2022-09-14, 最終更新日: 2024-11-13) |
| 主引用文献 | Sun, C.,Cheng, Y.,Liu, X.,Wang, G.,Min, W.,Wang, X.,Yuan, K.,Hou, Y.,Li, J.,Zhang, H.,Dong, H.,Wang, L.,Lou, C.,Sun, Y.,Yu, X.,Deng, H.,Xiao, Y.,Yang, P. Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents. Acta Pharm Sin B, 12:4446-4457, 2022 Cited by PubMed Abstract: Programmed cell death 1(PD-1)/programmed cell death ligand 1(PD-L1) have emerged as one of the most promising immune checkpoint targets for cancer immunotherapy. Despite the inherent advantages of small-molecule inhibitors over antibodies, the discovery of small-molecule inhibitors has fallen behind that of antibody drugs. Based on docking studies between small molecule inhibitor and PD-L1 protein, changing the chemical linker of inhibitor from a flexible chain to an aromatic ring may improve its binding capacity to PD-L1 protein, which was not reported before. A series of novel phthalimide derivatives from structure-based rational design was synthesized. was identified as the best inhibitor with promising activity, which not only inhibited PD-1/PD-L1 interaction (IC = 8.9 nmol/L), but also enhanced killing efficacy of immune cells on cancer cells. Co-crystal data demonstrated that induced the dimerization of PD-L1 proteins, thereby blocking the binding of PD-1/PD-L1. Moreover, exhibited a favorable safety profile with a LD > 5000 mg/kg and showed significant antitumor activity through promoting CD8 T cell activation. All these data suggest that acts as a promising small chemical inhibitor against the PD-1/PD-L1 axis and has the potential to improve the immunotherapy efficacy of T-cells. PubMed: 36561991DOI: 10.1016/j.apsb.2022.04.007 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (2.701 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






